Icos Corporation

Petra Pharma Corporation

Deltagen Research Labs, LLC

David L McElligott

Erik Christenson

Phyllis S Goldman

Anthony J DeMaggio

Eugene R Hickey

Gabrielle R Kolakowski

Kerry W Fowler

Jaimie Karyn Rueter

Aleksey I Gerasyuto

Danwen Huang

Qin Jiang

Pavel E Zhichkin

Sean Douglas Aronow

Graham Beaton

Daniel Lee Severance

Edward A Kesicki

Johnathan Alexander McLean

Markus Kristofer Dahlgren

Wilna J Moree

Tien Widjaja

Russell Dahl

Erin Danielle Anderson

Thomas Combs Irvin

Manoj Kumar

David John Fairfax

Christopher Glenn Mayne

Nicholas A Boyles

Jennifer Lynn Knight

Michael Brian Welch

Katelyn Frances Long

Helge A Reisch

Dan Herendeen

Jaimie E Bertino

Lisa H Bourdon

Ren Hua Song

Kannan Karukurichi Ravi

Shulu Feng

Anke Klippel-Giese

Anthony J Demaggio

Loredana Puca

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, W, X, Y, s, and Ring A are as described herein.

Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease

The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition, there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro and in vivo are also provided.

Human poly(ADP-ribose) polymerase 2 materials and methods

The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula:or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q, Qand Y are those defined herein.

PARP inhibitors

Human poly (ADP-ribose) polymerase 2 materials and methods

Growing community of inventors

Bothell, WA, United States of America

David L McElligott